Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Sociedade Brasileira de Proteção Radiológica - SBPR
2019
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=722280899014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Preclinical dosimetric evaluation of Ixolaris labeled with 99mTc and Translational Model Sarah C. S. Soriano Thiago Barboza Sérgio A. Lopes Souza Lidia V. Sá Biología 99mTc SPECT Ixolaris Preclinical dosimetric imaging dosimetry method This study aimed to investigate 99mTc- Ixolaris uptake by body in mice by means of an scintigraphic imaging dosimetry method to estimate the absorbed and effective doses resulting from the diagnosis of melanoma and metastases in humans. C57BL6 mice induced animals with cell line B16-F10 murine melanoma were tested. It was determined by Single Photon Emission Tomography Computed (SPECT) images a latency period of 15 to 21 days for the development of lung metastasis in mice. The radiopharmaceutical was intravenously administered in a caudal vein, and SPECT images were acquired approximately at 0.5 h, 1.5 h, 2.5 h, 3.5 h and 24 h postadministration for analysis and quantification. The biokinetics model was determined and cumulative activity to estimate the absorbed dose in each organ was calculated. The mass and metabolic differences between mice and humans were considered and used to extrapolate the data for different scales. Absorbed doses in irradiated target organs were calculated for the source organs based on dose factors provided by the software MIRDOSE and Olinda/EXM. Afterwards, the effective doses were estimated. The metabolic differences were 7,02 in this study. The dosimetric results indicated an estimated effective dose of 4.3 mSv for diagnostic exams conducted in human melanoma patients for an administered activity of 25.7 MBq. Comparing with effective doses resulting from other 99mTc diagnostic techniques, effective dose ranging from 0.6 to 4.8 mSv it was concluded that the procedure should proceed into a Clinical Phase in humans. 2019 artículo científico 2319-0612 https://www.redalyc.org/articulo.oa?id=722280899014 en http://www.redalyc.org/revista.oa?id=7222 Brazilian Journal of Radiation Sciences application/pdf Sociedade Brasileira de Proteção Radiológica - SBPR Brazilian Journal of Radiation Sciences (Brasil) Num.3 Vol.7